Glycolipid antigen presented by CD1d

The natural killer T cell ligand refers to glycolipid antigens, such as alpha-galactosylceramide (αGalCer), that are presented by the non-polymorphic MHC class I-like molecule CD1d on antigen-presenting cells. These ligands are specifically recognized by the invariant TCR of type I natural killer T (iNKT) cells, leading to rapid cytokine secretion and modulation of both innate and adaptive immune responses[2][4][8]. Recognition involves direct interaction between the glycolipid, CD1d, and the iNKT cell TCR, with structural modifications to the glycolipid altering binding affinity and biological outcome[2]. These ligands play roles in immune surveillance, inflammation, and have been explored for immunotherapy in cancer and infectious diseases, but they are not conventional drug targets themselves—rather, the CD1d–TCR axis is the target of therapeutic interest. The queried term "Natural killer T cell ligand" is not the name of a single, specific molecular target, but rather a broad class of molecules (glycolipids presented by CD1d) that activate natural killer T cells. The direct therapeutic targets in this pathway are the CD1d molecule and the iNKT cell T cell receptor, not the ligand itself. If you need structured information on CD1d or the iNKT cell TCR, please clarify or submit a new query for those specific targets.

Other names

CD1d-restricted lipid antigeniNKT cell ligandtype I natural killer T cell ligandalpha-galactosylceramide (αGalCer)CD1d-presented glycolipid

These glycolipids are presented by CD1d on antigen-presenting cells and recognized by the T cell receptor (TCR) of invariant natural killer T (iNKT) cells, triggering immune activation or modulation depending on the glycolipid structure and context[2][4].